Largest reported organ-on-a-chip screen ever performed on a 3D angiogenesis assay
LEIDEN, the Netherlands, May 27, 2021 / B3C newswire / -- MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate® technology offers the scalability and the throughput needed for drug discovery studies.
“We are very proud to open up this new center,” said Jos Joore, CEO of MIMETAS. “Our new Phenotypic Screening Center facilitates high-throughput organ-on-a-chip screening combined with high-content imaging and machine learning data analysis to identify drug candidates for today’s unmet medical needs. Our customers understand that human-relevant disease models should be at the basis of every drug discovery effort. Moreover, these cutting-edge technologies stimulate the creativity and purpose of our scientists to make a difference in the lives of patients.”
Largest Organ-on-a-Chip compound screen
MIMETAS recently reported a successful 1,546 compound screen in duplicate on a 3D angiogenesis assay in the OrganoPlate® 3-lane 64. Promising hit compounds from this screen are currently under investigation. “To our knowledge, this is the largest organ-on-a-chip screen ever reported,” explained Joore. “We partner with large pharmaceutical companies, that need our disease model screening expertise, and can bring promising candidates to the clinic fast. In this way, we make sure that we bring novel drugs to patients in the most efficient manner.”
New energy-neutral laboratory
The brand-new screening center is located in the new head office of MIMETAS at the shore of the Old Rhine, the ancient northern border of the Roman Empire. It is the first energy-neutral laboratory building in the Netherlands. This sustainable building has accomplished a 40% carbon dioxide reduction by reusing materials from a former Leiden University complex. Joore adds: “It is highly inspiring to perform our research surrounded by materials recycled from labs where Nobel-prize winners have done their groundbreaking science.”
For high resolution please click the image.
About MIMETAS
MIMETAS is a global leader in disease modeling using organ-on-a-chip technology. Its proprietary OrganoPlate® platform supports the development and high-throughput screening of physiologically relevant disease models. The company offers its technology and know-how to co-develop novel therapies and as off-the-shelf products and services. MIMETAS works with most top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown to a multinational company with operations in Asia, Europe, and the United States.
Contact
Mieke Doornbos
Director of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Humans; Models, Biological; Biological Assay; High-Throughput Screening Assays; Research; Drug Development; Phenotype; Cell Culture Techniques; Carbon Dioxide; Microfluidics; Drug Discovery; Laboratories; Data Analysis; Lab-On-A-Chip Devices; Molecular Imaging; Machine Learning; Pharmaceutical Preparations; Biotechnology; Netherlands
Published by B3C newswire